|Day Low/High||19.00 / 19.89|
|52 Wk Low/High||12.90 / 28.35|
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Proof of Concept Trial to Support Potential Future Utility of MYDICAR in LVAD Population
Conference Call Today at 8:30 a.m. Eastern Time
Investor Call Scheduled for 8:30am Eastern on Thursday, August 7, 2014
License Brings Novel Gene Therapy Approach for in situ Targeting of Multi-Potent Stem Cells for the Heart
These stocks rising on unusual volume are within range of triggering breakout trades.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
-- Conference Call Today at 4:30 p.m. Eastern Time --
--Dr. Roger J. Hajjar, Expert on SERCA2a in Heart Failure, Will Present--
MYDICAR is First Gene Therapy Reported to Receive Breakthrough Designation From FDA's Center for Biologics Evaluation and Research (CBER)
Conference Call Today at 4:30 p.m. Eastern Time
CUPID 2 Results Expected in April 2015
Servier Receives Exclusive Option to Enter Into Worldwide, Ex-U.S., Research Collaboration and License for Celladon's Novel Small Molecule SERCA2b Modulators for the Treatment of Diabetes and Metabolic Diseases
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.